About Vaxil bio ltd.
Vaxil Bio Ltd.: Revolutionizing the Future of Cancer Treatment
Vaxil Bio Ltd. is a biotechnology company that specializes in developing innovative immunotherapies for cancer treatment. The company's mission is to provide patients with safe and effective treatments that can improve their quality of life and increase their chances of survival.
With a team of experienced scientists, researchers, and clinicians, Vaxil Bio Ltd. has been at the forefront of cancer research for over a decade. The company's cutting-edge technology platform allows it to identify unique tumor-associated antigens (TAAs) that can be targeted by the immune system to fight cancer cells.
One of Vaxil Bio Ltd.'s most promising products is ImMucin™, a therapeutic vaccine designed to stimulate an immune response against multiple types of cancers. ImMucin™ targets a specific TAA called MUC1, which is overexpressed in many types of tumors but not in normal tissues.
Clinical trials have shown that ImMucin™ can induce strong immune responses in patients with various types of solid tumors, including breast cancer, ovarian cancer, lung cancer, and colon cancer. Moreover, ImMucin™ has been well-tolerated by patients without causing significant side effects.
Another product under development by Vaxil Bio Ltd. is SM-88, an oral medication designed to disrupt multiple metabolic pathways essential for tumor growth and survival. SM-88 combines four drugs that target different aspects of tumor metabolism: methoxsalen (a DNA intercalator), phenytoin (a sodium channel blocker), sirolimus (an mTOR inhibitor), and metformin (an AMPK activator).
Preclinical studies have shown that SM-88 can inhibit the growth and metastasis of various types of cancers both in vitro and in vivo models. Moreover, SM-88 has synergistic effects when combined with other anticancer agents, such as chemotherapy and immunotherapy.
Vaxil Bio Ltd. is also exploring other potential applications of its technology platform, such as personalized cancer vaccines and CAR-T cell therapies. The company has established collaborations with academic institutions, hospitals, and biopharmaceutical companies to advance its research and development programs.
In addition to its innovative products, Vaxil Bio Ltd. has a strong intellectual property portfolio that includes patents covering its technology platform and product candidates. The company has also received grants from government agencies and non-profit organizations to support its research activities.
Overall, Vaxil Bio Ltd. is a promising biotechnology company that is dedicated to improving the lives of cancer patients worldwide. With its unique approach to immunotherapy and metabolic disruption, Vaxil Bio Ltd. has the potential to revolutionize the future of cancer treatment.
If you are interested in learning more about Vaxil Bio Ltd.'s products or partnering opportunities, please visit our website at vxlbio.com or contact us directly at info@vxlbio.com.